Clinicopathological factors associated with HER2-positive gastric cancer

Abstract

BACKGROUND The treatment of patients with advanced gastric cancer remains a most challenging task in the clinical practice. Recently, targeted therapies have significantly impacted the treatment strategy for many common malignancies. The use of trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2; also known as ERBB2… (More)
DOI: 10.1097/MD.0000000000008437

5 Figures and Tables

Topics

  • Presentations referencing similar topics